An analysis of NICEs 'restricted' (or 'optimized') decisions

PharmacoEconomics

Volumn 28, Issue 11, 2010, Pages 987-993

  O'Neill, Phill ^a   Devlin, Nancy J ^a  

^a Office of Health Economics   (United Kingdom)

Author keywords

Cost effectiveness; Decision making; Formularies; Health policy

Indexed keywords

ANALYZER; ARTICLE; CALCULATION; DECISION MAKING; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; LICENCE; MEDICAL TECHNOLOGY; NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED KINGDOM; BIOMEDICAL TECHNOLOGY ASSESSMENT; HEALTH CARE PLANNING; HEALTH CARE POLICY; NATIONAL HEALTH SERVICE; PHARMACOECONOMICS; STATISTICS;

DRUG;

ECONOMICS, PHARMACEUTICAL; GREAT BRITAIN; HEALTH PLANNING ORGANIZATIONS; HEALTH POLICY; HUMANS; PHARMACEUTICAL PREPARATIONS; PRACTICE GUIDELINES AS TOPIC; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 77958005922     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11536970-000000000-00000     Document Type: Article

References (10)

1. Devlin N, Parkin D. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13(5):437-52
2. Dakin H, Devlin N, Odeyemi I. Yes, no or 'yes, but...': a multinomial model of NICE decision-making. Health Policy 2006;77:352-67
3. National Institute for Health and Clinical Excellence. NICE says "yes" to over 80 percent of treatments. London: NICE, 2010 Jul. 21 [online]. Available from URL: http://www.nice.org.uk/newsroom/news/NICEsaysYes. jsp [Accessed 2010 Aug. 4]
4. Electronic Medicines Compendium (eMC). 2010 [online]. Available from URL: http://emc.medicines.org.uk/[Accessed 2010 Aug. 5]
5. National Institute for Health and Clinical Excellence. Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy [NICE technology appraisal guidance 171]. London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11898/44627/44627.doc [Accessed 2010 Aug. 5]
6. National Institute for Health and Clinical Excellence. Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy: costing template and report. Implementing NICE guidance: NICE technology appraisal guidance 171. Sheet "Step 2 Costing Template". London: NICE, 2008 [online]. Available from URL: http://guidance.nice.org.uk/ TA171/CostingStatement/xls/English [Accessed 2010 Aug. 5]
7. National Institute for Health and Clinical Excellence. Alzheimer's disease: donepezil, galantamine, rivastigmine (review) and memantine. Costing report and template. London: NICE, 2007 [online]. Available from URL: http://guidance.nice.org.uk/TA111/CostingReport/xls/English [Accessed 2010 Aug. 5]
8. National Institute for Health and Clinical Excellence. Osteoporosis: secondary prevention including strontium ranelate. Costing template. London: NICE, 2008 [online]. Available from URL: http://guidance.nice.org.uk/TA161/ CostingTemplate/xls/English [Accessed 2010 Aug. 5]
9. National Institute for Health and Clinical Excellence. Ankylosing spondylitis: adalimumab, etanercept and infliximab. Costing template. London: NICE, 2008 [online]. Available from URL: http://guidance.nice.org.uk/TA143/ CostingTemplate/xls/English [Accessed 2010 Aug. 5]
10. National Institute for Health and Clinical Excellence. Osteoporosis: primary prevention. Costing template. London: NICE, 2008 [online]. Available from URL: http://guidance.nice.org.uk/TA160/CostingTemplate/xls/English [Accessed 2010 Aug. 5]